Abbott Laboratories

Item 7.01 Regulation FD Disclosure. On August 20, 2026, Abbott issued a press release announcing the settlement of a portion of its litigation involving its specialty formulas for preterm infants. A copy of the press release is furnished hereto as Exhibit 99.1 and is incorporated herein by reference. The information contained in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference to such filing.

Item 8.01 Other Events. As previously reported in Abbott’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, Abbott is a defendant in numerous lawsuits alleging that preterm infants developed necrotizing enterocolitis (“NEC”) as a result of being administered certain of Abbott’s preterm infant formula products. In a July 2024 Missouri state court trial, a jury awarded a plaintiff (“Gill”) $495 million in damages, which Abbott appealed to the Missouri Court of Appeals in December 2024. The Missouri Court of Appeals affirmed the Gill verdict in May 2026. On August 20, 2026, rather than continuing to appeal or paying approximately $600 million (representing the Gill judgment plus accrued interest to date), Abbott entered into agreements to resolve the Gill lawsuit as well as NEC claims asserted on behalf of approximately 2,000 additional infants for an aggregate amount of approximately $670 million. These agreements are a compromise of disputed claims and not in any way an admission of liability. While Abbott remains confident in the safety of these products and the science supporting them, the company believes these agreements are in its best long-term interest and represent a constructive step toward substantially resolving the overall litigation. Following these agreements, there are approximately 1,700 lawsuits pending in federal and state courts involving claims on behalf of approximately 12,700 individual infants. That population includes claims on behalf of individuals who named both Abbott and Mead Johnson as defendants without identifying which manufacturer’s formula was administered, who were diagnosed with NEC before receiving any formula, who were never diagnosed with NEC, and who appear in multiple lawsuits in different jurisdictions. Abbott continues to work to identify and eliminate such claims and others like them.